BIOMAT Database Logo BIOMAT Database Logo

Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. 1993

E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Carpibem, Rueil Malmaison, France.

A series of 1-benzylbenzimidazole and 3-benzylimidazo[4,5-b]pyridine substituted in the 2-position by an alkanoic or mercaptoalkanoic acid chain was synthesized for evaluation as potential thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonists. The affinity of each compound for washed human platelet TXA2/PGH2 receptors was determined by radioligand binding studies using [125I]PTA-OH. Structure-activity relationships led to the conclusions that 2-alkanoic acid derivatives were slightly more potent than 2-mercaptoalkanoic acids and that compounds possessing a 3,3-dimethylbutanoic acid in the 2-position were definitely the most potent with Ki values of 4-39 nM (11a, 11g-x, 37a, 37f-o, 23a-c). The replacement of this 3,3-dimethylbutanoic acid side chain by a shorter one led to a marked decrease of affinity (11b and 11c; Ki = 5600 and 1700 nM, respectively). Compounds of benzimidazole and imidazo[4,5-b]pyridine series displayed similar potencies (11q and 23c have Ki values of 6 and 7 nM, respectively). The interesting pharmacological profile of compound 23a (UP 116-77: 4-[3-[(4-chlorophenyl)methyl]-6-chloroimidazo[4,5-b]pyridin-2-yl]- 3,3-dimethylbutanoic acid) and its excellent tolerance led us to select this derivative for further development.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Imidazo[4,5-b]pyridine derivatives of potential tuberculostatic activity. Part 1: Synthesis and quantitative structure-activity relationships.
February 1991, Archiv der Pharmazie,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Synthesis and evaluation of novel thiazolidine derivatives as thromboxane A2 receptor antagonists.
March 1994, Chemical & pharmaceutical bulletin,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Synthesis and evaluation of gastroprotective activity of omeprazole related benzimidazole, imidazo[4,5-b]pyridine and quinoxaline 2-substituted derivatives.
September 1993, Farmaco (Societa chimica italiana : 1989),
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Synthesis and biological properties of imidazo-[4,5-b]-pyridine derivatives.
January 1982, Polish journal of pharmacology and pharmacy,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
May 2018, Bioorganic & medicinal chemistry,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Imidazo[4,5-b]pyridine derivatives of potential tuberculostatic activity, II: Synthesis and bioactivity of designed and some other 2-cyanomethylimidazo[4,5-b]pyridine derivatives.
September 1991, Archiv der Pharmazie,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Synthesis and evaluation of novel nonpeptide angiotensin II receptor antagonists: imidazo[4,5-c]pyridine derivatives with an aromatic substituent.
March 1995, Chemical & pharmaceutical bulletin,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.
March 2017, Molecules (Basel, Switzerland),
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.
May 1994, Journal of medicinal chemistry,
E Nicolaï, and J Goyard, and T Benchetrit, and J M Teulon, and F Caussade, and A Virone, and C Delchambre, and A Cloarec
Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.
August 2017, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!